Immunocore Holdings Future Growth
Future criteria checks 1/6
Immunocore Holdings is forecast to grow earnings and revenue by 5.8% and 13.9% per annum respectively. EPS is expected to grow by 4.6% per annum. Return on equity is forecast to be -49.4% in 3 years.
Key information
5.8%
Earnings growth rate
4.6%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 13.9% |
| Future return on equity | -49.4% |
| Analyst coverage | Good |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 376 | -103 | -34 | -50 | 11 |
| 12/31/2025 | 351 | -73 | -36 | -44 | 15 |
| 12/31/2024 | 311 | -44 | 21 | 20 | 15 |
| 9/30/2024 | 296 | -47 | 20 | 22 | N/A |
| 6/30/2024 | 281 | -55 | 9 | 11 | N/A |
| 3/31/2024 | 265 | -60 | -15 | -12 | N/A |
| 12/31/2023 | 249 | -55 | -2 | 3 | N/A |
| 9/30/2023 | 237 | -69 | 5 | 10 | N/A |
| 6/30/2023 | 220 | -61 | 6 | 12 | N/A |
| 3/31/2023 | 201 | -52 | -6 | -1 | N/A |
| 12/31/2022 | 174 | -53 | -51 | -49 | N/A |
| 9/30/2022 | 114 | -62 | -55 | -54 | N/A |
| 6/30/2022 | 82 | -112 | -96 | -94 | N/A |
| 3/31/2022 | 53 | -156 | -134 | -133 | N/A |
| 12/31/2021 | 36 | -180 | -144 | -143 | N/A |
| 9/30/2021 | 37 | -150 | -137 | -135 | N/A |
| 6/30/2021 | 39 | -139 | -111 | -110 | N/A |
| 3/31/2021 | 42 | -116 | -83 | -78 | N/A |
| 12/31/2020 | 41 | -101 | -88 | -84 | N/A |
| 9/30/2020 | 37 | -105 | -91 | -86 | N/A |
| 6/30/2020 | 34 | -109 | -137 | -131 | N/A |
| 3/31/2020 | 33 | -120 | -146 | -141 | N/A |
| 12/31/2019 | 34 | -138 | -142 | -136 | N/A |
| 12/31/2018 | 30 | -91 | -26 | -21 | N/A |
| 12/31/2017 | 19 | -66 | N/A | -82 | N/A |
| 12/31/2016 | 20 | -29 | N/A | -45 | N/A |
| 12/31/2015 | 17 | 20 | N/A | -26 | N/A |
| 9/30/2014 | 10 | -9 | N/A | 65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6YG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6YG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6YG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6YG's revenue (13.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 6YG's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6YG is forecast to be unprofitable in 3 years.